Downtown Paris Hotel Offers Photo Finish for Tour de France

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Downtown Paris Hotel Offers Photo Finish for Tour de France

PARIS--(Marketwired - Jun 21, 2013) - The Tour de France is the world's biggest cycling race, and this year it celebrates 100 years with new stage towns, multiple climbs and a new route. To see how it all ends, one could watch it on TV or read about it online, but those who want to be there amidst the first-place cyclist's glory (and the agony of the second-place cyclist's defeat), there's no better place than the Renaissance Paris Arc de Triomphe Hotel.

This five star Paris hotel is right next to the race's finish line on the Champs Elysées, so guests can feel the excitement first-hand. This year's race begins on 29 June and runs through 21 July, covering a total of 3,404 kilometres and 21 stages.

Before cyclists arrive in Paris next to this hotel near Champs-Elysées , they'll pass through seven flat stages, five hilly stages, six mountain stages with four summit finishes, two individual time trial stages and one team trial stage with only two days of rest. The 100 th anniversary race will also include 10 new stage towns: Porto-Vecchio, Bastia, Ajaccio, Calvi, Cagnes-sur-Mer, Saint-Gildas-des-Bois, Saint-Pourçain-sur-Sioule, Givors, Chorges and Annecy-Semnoz.

For the first time in race history, the route will include Corse-du-Sun and Haute-Corse, departments in metropolitan France that have never before hosted the Tour. After the route hits these two it will stay entirely within France for the first time since the 2003 race. Other changes for this year's race include both individual and team time trials, and two climbs up the Alpe-d'Huez plus three additional summits.

After booking a stay at this downtown Paris hotel, get full details on the 2013 Tour de France by visiting http://www.letour.fr/le-tour/2013/us/ .

About the Renaissance Paris Arc de Triomphe Hotel In such an iconic city, not just any hotel will do. Those looking to experience the glamour of Paris' past without losing the pulse of the present will find what they're looking for at the Renaissance Paris Arc de Triomphe Hotel. With a breathtaking contemporary design by Christian de Portzamparc, this five-star hotel near Champs- Elysées Avenue has become a hot spot for both visitors and locals. At Makassar Restaurant and Lounge, the global spice trade serves as inspiration for a creative menu that fuses contemporary French cuisine with Indonesian flavors. Guests can also gather in one of four meeting rooms, whether meeting with potential clients or hosting an intimate celebration for 30. Accommodations are clean in design and warm in ambience, and feature custom wallpaper, a modern color palette, stunning views from floor-to-ceiling windows (some rooms have balconies), coffee/tea service, Internet access, a large desk and bed built with a thick mattress, cotton linens and fluffy pillows. In the morning, stroll to the Marché poncelet, one of the city's oldest open-air markets, or stay on a more traditional track with a visit to the fitness center or Parc Monceau, an English-style garden whose 1-kilometre track is a favorite with local joggers.

CONTACT: Renaissance Paris Arc de Triomphe Hotel 39 Avenue de Wagram Paris, 75 017 France 33-1-5537 5537 http://www.marriott.com/hotels/travel/parwg-r...phe-hotel/

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 36

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 26

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 35

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 37

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 31

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 34

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Bank of Canada Considers Interest Rate Cuts Amid Growth Concerns

Updated Category News Views 91

Bank of Canada Considers Possible Rate Cuts Recent discussions reported by the Financial Times reveal that Governor Tiff Macklem of the Bank of Canada has started exploring the possibility of increasing the pace at which interest rates could be cut. This potential shift highlights the Bank's response to growing concerns about the Canadian economy's current dynamics....

Continue Reading
Photonics Market Poised for Massive Growth by 2030

Updated Category News Views 151

Understanding the Photonics Market Growth The photonics industry is on an impressive trajectory, with projections indicating it will grow significantly over the coming years. Experts foresee the market expanding from approximately USD 1,093.96 billion to an astounding USD 1,481.80 billion by 2030, reflecting a compound annual growth rate (CAGR) of around 6.3%. This rapid...

Continue Reading
Brookfield Infrastructure Plans Redemption of Preferred Units

Updated Category News Views 154

Brookfield Infrastructure Announces Series 3 Redemption Plan BROOKFIELD, News - Brookfield Infrastructure Partners L.P. (TSX: BIP.UN; NYSE: BIP) has announced its intention to redeem all outstanding Cumulative Class A Preferred Limited Partnership Units, Series 3 (the “Series 3 Preferred Units”). This strategic decision aims to enhance their portfolio's financial...

Continue Reading
How a $1000 Investment in Enphase Energy Grew to $3200

Updated Category News Views 147

Transforming $1000 into $3200 with Enphase Energy Investing can be a journey filled with uncertainties, but the story of Enphase Energy (NASDAQ: ENPH) reveals a powerful lesson in the potential of financial growth. Over the past five years, Enphase Energy has impressively outperformed many market benchmarks, achieving a remarkable annualized return of 26.49%. At present,...

Continue Reading
Investors Should Pay Attention: Rocket Pharmaceuticals Lawsuit Update

Updated Category News Views 191

The Class Action Lawsuit Against Rocket Pharmaceuticals Recently, investors of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) have been advised to participate in a class action lawsuit for potential securities fraud. This lawsuit arises from significant concerns over the company's disclosure practices and the impact of leadership decisions on stock performance. If you are an...

Continue Reading